Q3 EPS Estimates for Scholar Rock Cut by HC Wainwright

Key Points

• HC Wainwright lowered Scholar Rock’s Q3 2026 EPS estimate to a loss of $0.84 per share from $0.82, while maintaining a Buy rating and a $65 price target.
• Analyst sentiment remains broadly positive, with MarketBeat reporting an average Buy rating and an average price target of $56.79; the company’s latest quarterly loss of $0.84 per share matched consensus.
• Scholar Rock shares opened at $51.89, down 1.9%, while insiders sold $923,108 worth of stock over the past three months, primarily to cover tax obligations tied to equity awards.

Scholar Rock Holding Corporation (NASDAQ:SRRK - Free Report) - HC Wainwright cut their Q3 2026 earnings per share estimates for Scholar Rock in a report issued on Friday, August 7th. HC Wainwright analyst A. Maldonado now anticipates that the company will earn ($0.84) per share for the quarter, down from their previous forecast of ($0.82). HC Wainwright currently has a "Buy" rating and a $65.00 price objective on the stock. The consensus estimate for Scholar Rock's current full-year earnings is ($3.25) per share. HC Wainwright also issued estimates for Scholar Rock's Q4 2026 earnings at ($0.78) EPS, FY2026 earnings at ($3.29) EPS, FY2027 earnings at ($2.45) EPS, FY2028 earnings at ($0.86) EPS, FY2029 earnings at $0.35 EPS and FY2030 earnings at $1.40 EPS.

A number of other equities research analysts also recently issued reports on SRRK. Canaccord Genuity Group initiated coverage on shares of Scholar Rock in a report on Monday, April 20th. They issued a "buy" rating and a $62.00 price target on the stock. BMO Capital Markets reaffirmed an "outperform" rating and set a $76.00 target price on shares of Scholar Rock in a report on Friday. Barclays raised their price target on shares of Scholar Rock from $53.00 to $55.00 and gave the company an "overweight" rating in a report on Friday, May 8th. Weiss Ratings restated a "sell (d-)" rating on shares of Scholar Rock in a research report on Friday, July 17th. Finally, Wedbush reaffirmed an "outperform" rating and issued a $58.00 price target on shares of Scholar Rock in a report on Monday. Four research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Buy" and an average target price of $56.79.

Scholar Rock Stock Down 1.9%

Shares of NASDAQ SRRK opened at $51.89 on Tuesday. Scholar Rock has a 52 week low of $27.07 and a 52 week high of $58.49. The business has a 50-day simple moving average of $50.15 and a two-hundred day simple moving average of $47.92. The company has a quick ratio of 8.64, a current ratio of 8.64 and a debt-to-equity ratio of 0.71. The company has a market cap of $6.32 billion, a P/E ratio of -15.04 and a beta of 0.69.

Scholar Rock (NASDAQ:SRRK - Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.84) EPS for the quarter, hitting analysts' consensus estimates of ($0.84). During the same period in the prior year, the business earned ($0.98) earnings per share.

Insider Activity

In other news, Director Michael Gilman sold 2,544 shares of the business's stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $53.87, for a total value of $137,045.28. Following the completion of the sale, the director directly owned 59,511 shares in the company, valued at approximately $3,205,857.57. The trade was a 4.10% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Jeffrey S. Flier sold 3,053 shares of the company's stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $53.88, for a total transaction of $164,495.64. Following the completion of the sale, the director directly owned 27,856 shares of the company's stock, valued at $1,500,881.28. This trade represents a 9.88% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders sold 17,149 shares of company stock worth $923,108. 10.30% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. GAMMA Investing LLC lifted its stake in shares of Scholar Rock by 20.8% in the 2nd quarter. GAMMA Investing LLC now owns 1,406 shares of the company's stock valued at $77,000 after acquiring an additional 242 shares during the last quarter. Values First Advisors Inc. grew its position in Scholar Rock by 1.5% during the 1st quarter. Values First Advisors Inc. now owns 18,850 shares of the company's stock worth $927,000 after acquiring an additional 286 shares during the last quarter. IFP Advisors Inc increased its stake in Scholar Rock by 294.1% in the 4th quarter. IFP Advisors Inc now owns 603 shares of the company's stock worth $27,000 after purchasing an additional 450 shares during the period. EverSource Wealth Advisors LLC lifted its position in Scholar Rock by 151.3% in the fourth quarter. EverSource Wealth Advisors LLC now owns 872 shares of the company's stock valued at $38,000 after purchasing an additional 525 shares during the last quarter. Finally, California State Teachers Retirement System lifted its position in Scholar Rock by 0.9% in the second quarter. California State Teachers Retirement System now owns 62,372 shares of the company's stock valued at $2,209,000 after purchasing an additional 577 shares during the last quarter. 91.08% of the stock is owned by institutional investors.

About Scholar Rock

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company's research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock's approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company's lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source